Tenaya Therapeutics TNYA 深 沪
等待开盘 09-17 09:30:00 美东时间
0.6621
-0.008
-1.25%
华盛通- 最 高0.6739
- 今 开0.6618
- 成交量 73.21万股
- 最 低 0.661
- 昨 收 0.6705
- 总市值 1.48亿
- 52周最高 2.35
- 市盈率 静 --
- 换手率 0.33%
- 52周最低 0.5316
- 委 比 -27.12%
- 总股本 2.24亿
- 历史最高 32.00
- 量 比 0.66
- 振 幅 1.92%
- 历史最低 0.36
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Ther...
09-14 20:34
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.110 mil...
08-06 06:39
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Tenaya Therapeutics announced that its management will host 1x1 investor meetings at the Canaccord Genuity 46th Annual Growth Conference on August 11-12, 2026, in Boston. Eric Hyllengren, Tenaya’s CFO, will participate in a fireside chat on August 11 at 12:30 pm ET. The live webcast and a 30-day replay will be available on Tenaya’s website. Tenaya is a biotech company focused on developing curative therapies for heart diseases, with a pipeline in...
08-04 20:05
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Inc. granted stock options to purchase 1,650,000 shares to its new CFO Eric Hyllengren and 187,200 shares to two new non-executive employees. The options have an exercise price of $0.8365 per share, vesting over four years, and are part of the 2024 Inducement Equity Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). Tenaya, a biotech company focused on developing curative therapies for heart disease, has a pipe...
07-15 01:00
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
06-03 04:32
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PKP2-related ARVC patients.
05-15 22:11
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
